Item 9 Labs Corp. Announces Reverse Stock Split Effectiveness

Item 9 Labs Corp.(OTC: INLB) (“Item 9 Labs” or the “Company”), a leading provider of comfortable cannabis health solutions for the modern consumer through the development of innovative products and proprietary delivery platforms, today announced  a 1-for-20 reverse split of its issued and outstanding common stock effective October 18, 2018.  The common stock will begin trading on a split-adjusted basis on October 18, 2018 on OTC Markets under the ticker symbol “INLBD”.  The “D” is appended at the end of the ticker symbol for twenty (20) trading days at which time the symbol will revert back to “INLB.”  There is no proportional split of the Company’s authorized share count.

The Company’s board of directors approved the reverse split by unanimous written consent on October 15, 2018. The Company’s shareholders approved the reverse stock split pursuant to a majority written consent of the shareholders on October 5, 2018.

By implementing the reverse stock split, the Company hopes to gain broader access to the institutional investment community and improve the marketability and liquidity of the common stock for its shareholders and investors.

The reverse split reduced the number of shares of the Company’s outstanding common stock from approximately 1.09 billion shares to approximately 55 million shares outstanding. Fractional shares will be rounded to the nearest whole number but every shareholder will be entitled to at least one whole share.

About Item 9 Labs Corp.:

Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.comand www.Item9labs.com.

Forward-Looking Statement:This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Media Contact:
Investor Relations:
Jeffrey Rassás
(480)463-4246 or (877)876-4868
Email: jeffrey@item9labs.com